Osteomielitis bacteriana: aspectos microbiológicos, clínicos, terapéuticos y evolutivos de 344 episodios by García del Pozo, Elena et al.
Rev Esp Quimioter 2018;31(3): 217-225 217
©The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 
International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
could influence its treatment and outcome. Aggressive surgery 
along with adequate antimicrobial therapy are mandatory for 
cure. 
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Osteomielitis bacteriana: aspectos 
microbiológicos, clínicos, terapéuticos y 
evolutivos de 344 episodios
RESUMEN
Introducción. La osteomielitis es una infección difícil de 
curar, de etiología múltiple y con una alta tasa de recidivas a 
pesar del empleo de tratamientos combinados médicos y qui-
rúrgicos. Hay muy pocas series amplias de aspectos generales 
de la osteomielitis publicadas hasta ahora.
Material y métodos. Se siguieron 344 pacientes adultos 
diagnosticados de osteomielitis durante > 1 año tras el alta 
médica. Se recogieron y analizaron sus características demo-
gráficas, microbiológicas, clínicas, terapéuticas y evolutivas.
Resultados. La edad media fue de 52,5 ± 18.3 años y 
233 (67,7%) eran hombres. Los principales tipos de osteomie-
litis fueron post-quirúrgica (31,1%), post-traumática (26,2%) 
y hematógena (23%). Tibia (24,1%) y fémur (21,8%) y Sta-
phylococcus aureus sensible a meticilina (29,6%) fueron los 
huesos y bacteria implicados con mayor frecuencia, respec-
tivamente. El tiempo medio de seguimiento fue de 12 (RIQ 
0-48) meses. Los reactantes de fase aguda estaban elevados 
en 73,6%. Los pacientes fueron tratados con uno (44,5% y 
26,7%), dos (30,1% y 21,8%) o más de dos antibióticos (15,2% 
y 6,1%) por vía IV y oral, respectivamente. La duración media 
de la terapia antimicrobiana IV/oral fue de 28,0 (RIQ 24-28) y 
19,5 (RIQ 4-56) días, respectivamente. Los β-lactámicos anti-
estafilocócicos cloxacilina/cefazolina (19,2%) y ciprofloxacino 
ABSTRACT
Introduction. Osteomyelitis is a difficult-to-cure infec-
tion, with high relapse rate despite adequate therapy. Large 
published osteomyelitis series in adults are rare.
Material and methods. A total of 344 adult osteomyeli-
tis patients were studied and followed > 12 months after hos-
pital discharge. Demographic, microbiological, clinical, thera-
peutic and outcome data were analyzed.
Results. Mean age was 52.5 ± 18.3 years and 233 (67.7%) 
were male. Main osteomyelitis types were post-surgical 
(31.1%), post-traumatic (26.2%) and hematogenous (23%). 
Tibia (24.1%) and femur (21.8%), and methicillin-susceptible 
S. aureus (29.6%) were the most commonly involved bone and 
bacteria, respectively. Median follow-up was 12.0 (IQR 0-48) 
months. Inflammatory markers were increased in 73.6%. Over-
all, patients were treated by IV and oral routes with one (IV: 
44.5%, oral: 26.7%), two (IV: 30.1%, oral: 21.8%) or ≥ 2 (IV: 
15.2%, oral: 6.1%) antibiotics. Median duration on IV/oral an-
timicrobials was 28.0 (IQR 24-28) and 19.5 (IQR 4-56) days, 
respectively. Anti-staphylococcal β-lactams cloxacillin/cefazo-
lin (19.2%) and ciprofloxacin (5.5%) were the most frequently 
used IV and orally, respectively. Overall 234 (68.0%) underwent 
surgery, 113 (32.8%) debridement, 97 (27.4%) debridement + 
muscle flap and 24 (7%) amputation. At the end of follow-up 
208 patients (60.6%) did not have relapsed. Operated patients 
had significantly less relapses (p<0.0001). A total of 23 (6.7%) 
died, 11 (3.2%) by infectious complications and 48 (14%) were 
lost in the follow-up.
Conclusions. Osteomyelitis is due to different causes 
complicating its therapy. Risk factors or causal microorganism 
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follow-up of treated bone infections. Imaging studies are es-
sential. X-ray images can show a lytic area with a periosteal 
reaction, but usually other studies as CT or MRI are needed 
to demonstrate the necrotic bone. Isotopic scans, like bone 
scintigraphy with Technetium99, Gallium67 or, more specifical-
ly, Indium111, can help to differentiate bone from soft tissue 
infection or inflammation. PET-CT is one of the best nuclear 
studies for osteomyelitis diagnosis, but is not available in many 
hospitals. Bone cultures, especially from surgical biopsies, are 
essential in the diagnosis. Staphylococcus aureus is the patho-
gen most frequently found, although more than one pathogen 
can be isolated from the cultures [1,4,8].
Treatment of osteomyelitis involves surgery and antibiot-
ic therapy. Surgery plays a key role especially in chronic os-
teomyelitis. An aggressive debridement of all necrotic tissues 
(bone and soft tissue) is essential. After debridement, it could 
be necessary to stabilize the bone and to provide a suitable 
soft tissue coverage. Reconstruction techniques provide ele-
ments to repair the bone, adding a vascularized coverage that 
increases antibiotic concentration into the bone and helps its 
healing. Extended antibiotic therapy without surgery can be 
curative in haematogenous and vertebral osteomyelitis, es-
pecially in children. In the remaining cases, it is a necessary 
complement to surgery. Usually a combination of antibiotics is 
necessary to avoid bacterial resistances after extended antimi-
crobial therapies [4,9–12]. 
We report here our 21-year experience treating osteomy-
elitis patients at the Hospital Universitario Central de Asturias 
(HUCA). Our descriptive study reports the causes, microbiology, 
(5,5%) fueron los antimicrobianos más frecuentemente usados 
por vía IV y oral, respectivamente. Un total de 234 pacientes 
(68%) fueron sometidos a cirugía, de ellos 113 (32,8%) a des-
bridamiento, 97 (27,4%) a desbridamiento + colgajo muscular 
y 24 (7%) a amputación. Un total de 208 pacientes (60,6%) no 
recidivaron. Los pacientes operados presentaron menos recidi-
vas (p<0,0001). Un total de 23 (6,7%) pacientes fallecieron, 11 
(3,2%) por complicaciones infecciosas y 48 (14%) se perdieron 
durante el seguimiento.
Conclusiones. La osteomielitis se debe a causas diversas 
que complican su abordaje terapéutico. Los factores de riesgo 
o microorganismos causales podrían influir en los resultados 
del tratamiento y en la remisión de la enfermedad. Una cirugía 
agresiva junto con un tratamiento antimicrobiano adecuado 
son imprescindibles para obtener la curación 
Palabras clave: osteomielitis, recidiva, factores de gravedad, desbridamien-
to, colgajo muscular, antibióticos
INTRODUCTION
Osteomyelitis is a bone marrow inflammation, usually 
caused by an infectious agent. It has a heterogeneous patho-
physiology, and is one of the most difficult infections to cure. 
The source of the infection may be haematogenous, acquired 
from a contiguous infectious focus or by direct inoculation 
into the bone. Osteomyelitis can be classified into acute, sub-
acute or chronic, according to the time of evolution. Acute os-
teomyelitis has usually a good response to antimicrobials and, 
if necessary, to surgery. On the opposite, chronic osteomyelitis 
represents a great therapeutic challenge, becoming surgery es-
sential to obtain the best results [1–4]. Several classifications of 
osteomyelitis have been reported so far, being that established 
by Cierny-Mader-Pennick and Waldvogel the most frequently 
used [5,6]. Waldvogel classification is based on the time course 
and etiopathology of the bone infection [5]. According to the 
time course, osteomyelitis could be acute or chronic; by its 
etiology, haematogenous or secondary to a contiguous focus 
of infection. Waldvogel classification includes also the pres-
ence or absence of vascular disease, giving a key role to tissue 
perfusion in the evolution of the bone infection. Cierny-Mad-
er-Pennick classification includes pathologic and immunologi-
cal approaches [6]. By the pathological approach osteomyelitis 
can be divided in four types (figure 1): I-Medullary, II-superfi-
cial, III-localized and IV-diffuse. It also classifies osteomyelitis 
patients in type A host, that has no comorbidities; type B host, 
that has one or two general diseases; and type C host, in which 
the risk of surgical treatment exceeds the cure benefits due to 
the carriage of several comorbidities [1,4,7]. 
The signs and symptoms of bone infection are non-spe-
cific very often. Low grade fever or local pain are usually pres-
ent, but others as limb swelling or erythema are occasional. 
Drainage, fistula or abscess can be more frequently observed 
in osteomyelitis caused by a contiguous focus. The main ab-
normalities found in blood tests are increased erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). Al-
though non-specific, these lab findings are very useful in the 
Figure 1  Cierny–Mader-Pennick classification of 
osteomyelitis. Anatomical: I- medullary, 
II- superficial, III- localized and IV- 
diffuse. Host immunity: type A host, 
without comorbidities; type B host, 
one or two general diseases; and type 
C host, the risk of surgical treatment 
exceeds the benefits because of 
comorbidities.
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tors, analytical tests and image studies were recorded as well. 
Treatment data, including type and duration of antimicrobi-
als, and type of surgical treatment were carefully registered. 
Follow-up, relapse and remission rates were also recorded. 
Relapse was considered when clinical findings or image signs 
of osteomyelitis reappeared. Osteomyelitis was considered in 
remission when no relapses were detected after a minimum 
12 months of follow-up. Remission time was considered as the 
time until relapse of bone infection, and when there was no 
relapse, the follow-up time. The study was retrospective de-
scriptive, with a level of evidence IV
Statistical analysis. Continuous variables are reported as 
mean ± SD or median (IQR) and categorical variables as n (%). 
The comparisons between the relapse and non-relapse cases or 
time free of disease were carried out by the t-test and the chi-
square or Fisher exact tests when appropriate, for continuous 
and categorical variables, respectively. SPSS v.22 (IBM, version 
22) software was used for statistical calculations. A 
P value <0.05 for a two-sided test was considered 
statistically significant.
RESULTS
Between 1994 and 2015, 402 patients were 
diagnosed with osteomyelitis at the HUCA Infec-
tious Diseases Unit and their medical charts were 
reviewed. Fifty-eight were excluded because of lack 
of confirmation of bone infection or missing key 
data after their transfer from other affiliated hos-
pitals for surgical therapy. Overall 344 patients, 233 
(67.7%) men and 121 (32.3%) women, fulfilled os-
teomyelitis criteria and were included in the study. 
Their mean age ± SD was 52.5 ± 18.3 years. The 
main types of bone infection were post-surgical 
(107 patients, 31.1%), post-traumatic (90 patients, 
26.2%) and haematogenous (52 patients, 23%). 
Other causes are shown in figure 2. The most fre-
quently involved bone was the tibia (24.1%), femur 
was the second one (21.8%) with knee joint (femur 
+ tibia) as the third most frequent location (10.8%). 
Vertebral osteomyelitis was found in 29 patients (8.4%). Other 
bone locations are shown in figure 3. The bone affected dif-
fered according to the type of osteomyelitis. Thus, in post-sur-
gical cases the bone most frequently affected was the femur; 
in post-traumatic cases was the tibia, in haematogenous os-
teomyelitis were tibia and vertebrae; and in pressure sores was 
the ischium followed by sacrum and femur.
Positive cultures were obtained from bone biopsies in 234 
cases (68%), blood cultures in 79 cases (23%) and from drain-
ing fistulas in 31 cases (9%). Staphylococcus aureus was the 
most frequently agent isolated on monomicrobial infections 
(29.6% of patients). The second and third most frequently iso-
lated microorganisms were Pseudomonas aeruginosa and me-
thicillin-resistant S. aureus (4.1% each, respectively). The rate 
of polymicrobial infection was 35.4%. Many others pathogens 
were found with a lower frequency, Staphylococcus epider-
bone involvement, lab parameters, risk factors and comorbid-
ities, antimicrobial and surgical therapies, cure rates, and re-
lapses in our large osteomyelitis cohort. 
MATERIAL AND METHODS
We performed a retrospective study of all diagnosed cas-
es of osteomyelitis/ bone infection between January 1st, 1994 
and October 1st, 2015 at the Hospital Universitario Central 
de Asturias (HUCA) and three other affiliated hospitals from 
the same region. Demographic data, types of bone infection 
(classified as hematogenous, post-traumatic, post-surgery, 
pressure sores, diabetic foot, chronic ischemia of lower limbs, 
neurophatic foot ulcer or others), bone affected and causal 
germen were registered. Other data, like osteomyelitis risk fac-
Figure 2 Causes of osteomyelitis
Figure 3 Bones affected.
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there was a statistically significant relationship 
between inflammatory markers elevation and 
the type of osteomyelitis, with post-surgical 
(ESR median value of 56.0 [IQR 26.0-99.0]) 
mm/h and CRP median value of 15.9 [IQR 2.3-
9.5] mg/dl, respectively), haematogenous (ESR 
median value of 54.0 [IQR 27.5-92.0] mm/h 
and CRP median value of 4.8 [IQR 1.4-11.6] 
mg/dl, respectively) and post-traumatic (ESR 
median value of 47.0 [IQR 22.5-77.3]) mm/h 
and CRP median value of 3.8 [IQR 0.8-10.0] 
mg/dl, respectively) osteomyelitis inducing the 
highest increase of these parameters (p<0.03 
when comparing ESR values of post-surgical 
or hematogenous versus post-traumatic os-
teomyelitis) (figure 4). Image studies, like CT, 
MRI or nuclear scans, provided the diagnosis 
of osteomyelitis in 52% of cases when con-
ventional radiography was not diagnostic. 
Osteomyelitis risk factors or comorbidities 
were classified in systemic and local. Among 
the systemic risk factors, diabetes, rheuma-
toid arthritis, immunosuppressive therapy or 
immunodeficiency were found. The most fre-
quent local risk factors were vascular (78 pa-
tients, 22.7%) and sensitivity abnormalities 
(55 patients, 16.0%), and highly-contaminated 
open bone fractures (38 patients, 11.0%). No 
osteomyelitis risk factors were found in 171 
(49.7%) of the cases, both systemic and local 
risk factors were observed in 78 (22.7%), only 
local risk factors in 55 (16%) and only systemic 
risk factors were found in 40 (11.6%.) patients. 
The type of risk factors changed significantly 
according to the osteomyelitis cause (p<0.001) 
(figure 5).
The treatment received by the patients 
was divided into antibiotic therapy, surgical 
treatment or both. Antibiotic therapy usually 
consisted in an intravenous (IV) cycle (median 
duration of antimicrobials 28.0 [IQR 24-28] 
days), followed for an oral cycle (median du-
ration of antimicrobials 19.5 [IQR 4-56] days). 
No differences in the prognosis of the patients 
according to the need of different antibiotic 
treatment regimens, IV or oral, were observed. 
Therapy duration might be biased by the 3 cases of vertebral 
osteomyelitis treated during 9 months. Overall, 3.8% of pa-
tients did not receive IV antimicrobials and for 6.4% of pa-
tients the type and duration of antimicrobials were unknown. 
Regarding IV antimicrobial therapy, 44.5% of cases received 
one antibiotic, 30.1% two antimicrobials and 15.2% more 
than 2 antibiotics. The antimicrobials most frequently used as 
IV monotherapy were cloxacillin (10.8% of all cases), cefazolin 
(8.4%) and amoxicillin-clavulanic acid (6.7%), and in associa-
tion vancomycin, ciprofloxacin and clindamycin. The associa-
midis (3.2%), Escherichia coli (2.3%), and Enterococcus fae-
calis, Enterococcus faecium, Proteus mirabilis, and anaerobes 
(<2%). Mycobacterium tuberculosis was isolated in 3 cases 
(0.9%). Overall 22 patients (6.4%) had negative cultures. 
Overall, 73.6% of the patients had increased inflammatory 
blood markers at the diagnosis of osteomyelitis. ESR median 
value was 54.0 [IQR 27.5-92.0] mm/h and CRP median value 
was 4.8 [IQR 1.4-11.6] mg/dl. Although there was an eleva-
tion of these biomarkers in most of the osteomyelitis patients, 
Figure 4  Inflammatory blood markers changes according to the 
osteomyelitis cause.
Figure 5  Risk factors differences according to the osteomyelitis 
cause.
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used in combination (14.2%), followed by clindamycin and cip-
rofloxacin. The oral antimicrobial association most commonly 
used was rifampicin + clindamycin (5.2%).
In our series, 234 (67.2%) of osteomyelitis patients under-
went surgery. Of them, surgery involved only debridement, ab-
scess drainage or joint lavage in 113 (32.8%) patients. Recon-
structive techniques, in addition to debridement, were applied 
in 97 (27.4%). They involved coverage with vascularized tissue, 
either free or pediculated, from muscle, fasciocutaneous or 
bone flaps. Partial or total limb amputation was performed in 
tions most commonly used were vancomycin + ciprofloxacin, 
cloxacillin + gentamycin and clindamycin + ciprofloxacin (2% 
each). Regarding oral antimicrobial therapy, 39.2% of patients 
did not receive any oral antibiotic and in 6.1%, the type of an-
timicrobials and/or its duration were unknown. Overall, 26.7% 
received oral antimicrobial monotherapy, 21.8% an association 
of 2 antibiotics and 6.1% more than 2 antibiotics. The oral 
antimicrobials most used as monotherapy were ciprofloxacin 
(5.5%), clindamycin (5.2%) and amoxicillin-clavulanic acid 
(4.4) , whereas rifampicin was the antibiotic most frequently 
Figure 6  Surgical approaches according to the osteomyelitis cause.
Figure 7  Relapse differences (A) and remission mean time (B) according to the osteomyelitis cause.
A B
Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodesE. García del Pozo, et al.
Rev Esp Quimioter 2018;31(3): 217-225 222
At 12 months of follow up, 224 patients (65.1%) did not 
show signs of osteomyelitis relapse. On October 1, 2015 when 
the study data collection was closed 208 patients (60.6%) 
were still in remission. That means that 16 patients (4.7%) re-
lapsed after 12 months of completing therapy. The remission 
mean time or time free of disease observed in our patients 
was 8.0 (IQR 8-36) months. Patients that underwent surgery 
had significantly less relapses compared to those without 
surgery (67/234 [28.6%] vs. 69/110 [62.7%], χ2=34.97, OR 
[95% CI] 4.19 [2.53-6.98], p<0.0001 by the Yates correction 
test). Regarding the remission mean time or time free of dis-
ease, patients that underwent surgery had a mean of 32.0 ± 
36.7 months vs. 7.9 ± 23.3 months for those without surgery 
(p<0.0001). Although all the types of surgery, amputation, 
bone debridement and bone debridement + reconstruction 
were significantly associated with less osteomyelitis relapses, 
when individually compared to patients without surgery no 
significant differences in infection relapse rate were observed 
among the surgical groups (8/24 [33.3%], 31/97 [32.0%] and 
28/113 [24.8%], p>0.9). Differences in relapse and remission 
time according to the type of osteomyelitis and surgical treat-
ment applied are shown in figure 7 and 8. 
DISCUSSION
Osteomyelitis is a very complex infection due to its varied 
etiology and associated factors, and requires a multidiscipli-
nary approach [1,9,13,14]. The diversity of all these elements 
influences the type of therapy administered and complicates 
the generalized implementation of a standardized therapeutic 
24 (7%) of cases. Surgical treatment significantly differed ac-
cording to the osteomyelitis cause (figure 6)
The patients’ median follow up was 12.0 (IQR 0-48) 
months. Forty-eight patients (14%) were lost for follow-up, 25 
(7.3%) of them were transferred to their original hospital or 
did not return for follow-up, and the remaining patients died 
during hospital admission. A total of 23 patients (6.7%) died 
during the follow up, 11 of them (3.2%) 30 days after hos-
pital admission because of sepsis and/or multi-organ failure 
related with bone infection. The 12 remaining patients (3.5%) 
died of other unrelated causes occurred during admission or 
follow-up. Other severe complications were due to adverse ef-
fects of antimicrobials, recurrence of cranial tumor in a patient 
with cranial osteomyelitis due to previous operation or parapa-
resis due to spinal cord compression in vertebral osteomyelitis. 
Main local complications were related to recurrence or persis-
tence of draining fistulae in 42 patients (12.2%) requiring new 
antimicrobial and/or surgical treatment, and even amputation 
in 3 patients. Total flap necrosis requiring a second surgery oc-
curred in 8 patients, 4 of them had osteomyelitis recurrence 
and 2 of these required limb amputation. Partial flap necro-
sis solved with another type of minor surgery, conventional 
heal dressings or vacuum therapy occurred in 7 patients, and 
only one of them had recurrence. Other 7 patients developed 
pseudoarthrosis, which was infected in only one of them. Four 
of these pseudoarthrosis patients underwent surgical correc-
tion with good evolution. Other complications were episodes 
of cellulitis, with isotopic scans negative for osteomyelitis and 
good response to antibiotics, osteoarthritis, joint stiffness, 
plantar sores, limb shortening or pathologic fractures. 
Figure 8  Relapse differences (A) and remission mean time (B) according to the surgical treatment 
received.
A B
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The optimal treatment of most osteomyelitis requires in 
most of the cases the combination of antimicrobial therapy 
and surgery. Antibiotic therapy is always provided, but the 
administration route and the duration are controversial. Years 
ago, very long cycles of antibiotics were commonly used, al-
though modern studies have not proved the benefit of extend-
ed antimicrobial therapy [15,20,21,23-28]. In our study the an-
tibiotic therapy was usually divided in two parts, one IV cycle 
lasting 2 to 4 weeks and an oral cycle lasting 6 to 8 additional 
weeks, along with surgery. Although the evolution of the pa-
tient, among other factors, influenced the duration of treat-
ment, the antibiotic therapy was prescribed and monitored 
always by the same infection team in this study and, there-
fore, the intrinsic variability of this parameter was minimized 
to some extent. No studies have shown which antimicrobial 
is more effective in osteomyelitis. There are studies designed 
to prove the efficacy of new antimicrobials in bone infections, 
but very few studies have compared different antibiotics and 
routes of administration. In spite of the predominance of S. 
aureus in osteomyelitis, many microorganisms may be in-
volved and antimicrobial combinations with good biofilm and 
bone penetration are mandatory [15, 20 ,21,23–28].
Surgical treatment is essential in the management of 
some types of osteomyelitis, but in others, like acute haemat-
ogenous osteomyelitis, it might not be necessary. Debridement 
of all necrotic tissues (bone and soft tissue) is the main surgi-
cal procedure. Bone instability or coverage defects as a con-
sequence of debridement need attention as well, as bone and 
soft tissue defect reconstruction might influence the outcome. 
A large number of techniques (bone substitutes with differ-
ent antibiotics, antibiotic-impregnated cement and beads, flap 
coverage, bone grafts...) can be used. As with antimicrobials, 
only descriptive reports of the different surgical techniques 
and their results have been reported, but no comparative stud-
ies of the different techniques have been published so far. Fur-
thermore no studies comparing coverage techniques plus bone 
debridement versus plain bone debridement, when there is no 
bone instability or coverage problems, have been reported. We 
could not find differences regarding osteomyelitis relapses 
when different types of surgical approaches were compared, 
amputation, bone debridement and bone debridement + re-
construction in our study. This might be due to the large het-
erogeneity of our osteomyelitis cases. A more homogeneous 
cohort including for instance only osteomyelitis of long bone 
might be more suitable to find differences among osteomyeli-
tis surgical treatments regarding the outcome. We think that 
providing vascularised tissues with flap reconstruction along 
with debridement improves the results of surgical treatment. 
Although our group lacks experience in new and promising 
treatments, like employment of bioactive glass or other bone 
substitutes, we plan to incorporate them in the near future 
as a complement to flap reconstruction [4,9,14,29–34]. There 
are other techniques that complement antibiotic and surgi-
cal approaches, like hyperbaric oxygen therapy. Increasing the 
oxygen supply to tissues to create a hyperoxic environment 
may have an antimicrobial effect that could help in refractory 
protocol. We report here our experience at the HUCA in the 
care of osteomyelitis patients during the past 21 years, paying 
special attention to the etiologic aspects and to the medical 
and surgical management of osteomyelitis.
Our osteomyelitis series is one of the largest published in 
the world literature and also has an extended follow-up period 
[15]. Jiang et al. reported 394 cases of long bone osteomyelitis 
from China, mostly post-traumatic [16]. Our study involves not 
only post-traumatic but also other types of bone infection. In 
our series, post-surgical was the most frequent type, followed 
by post-traumatic osteomyelitis. Other important causes were 
haematogenous osteomyelitis or pressure sores. Long bones, 
particularly tibia, were the bones more frequently affected, al-
though the location was influenced by the origin of the infec-
tious source [17]. 
S. aureus was the microorganism most frequently involved 
in osteomyelitis in ours and in previous reports, but nowadays is 
also common to find osteomyelitis due to multirresistant path-
ogens or to microorganisms associations. Biofilm is a typical ex-
ample for these associations and Staphylococcus spp. plays an 
important role in its formation. Biofilm is frequently found in 
orthopaedic prosthesis infections and its eradication is the main 
objective of the treatment. Other pathogens isolated on our se-
ries were coagulase-negative staphylococci, Streptococcus spp, 
P. aeruginosa, Enterobacter spp. and Enterococcus spp. Three 
cases had vertebral osteomyelitis caused by M. tuberculosis, an 
infection commonly reported in other bone infection series, but 
unusual in our environment [2,4,16–19]. 
Osteomyelitis manifestations are often very unspecific. 
Bone infection might be only suspected by the presence of 
draining fistulas or chronic wounds. Increased inflammatory 
markers may be of some help, although they are unspecific 
and show normal values in many cases, especially in chronic or 
latent infections as in our study [16]. Although many inflam-
matory blood markers have been studied, only ESR and CRP 
correlated with the development and evolution of osteomy-
elitis, as we also observed [20, 21]. Present research lines of 
our group and others are aimed at establishing a relationship 
between the carriage of different genetic polymorphisms of 
cytokines and other proinflammatory molecules and a predis-
position for the development of osteomyelitis or its evolution 
to chronicity [22].
Risk factors associated with osteomyelitis are very impor-
tant in the evolution and treatment of this infection. Wald-
vogel and Cierny-Mader-Pennick classifications include an 
special section devoted to risk factors. Of these, the most im-
portant are immunosuppression and poor blood supply [2]. For 
some osteomyelitis, such as post-traumatic or post-surgical, 
bone risk factors are not involved in its development, while in 
others, such as those due to pressure ulcers or in diabetic foot, 
poor blood supply and immunosuppression play an important 
role. In our study we have included patients with multiple risk 
factors and locations, which complicate outcome analysis, es-
pecially antimicrobial and surgical therapy success and infec-
tion relapse. 
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osteomyelitis [35,36]. The main challenge we face today is to 
ascertain which of these surgical and non-surgical techniques 
provide the greatest benefit for the cure of the infection and 
in which type of osteomyelitis would be more efficacious. 
In conclusion, osteomyelitis constitutes a complex infec-
tion with different causes and many associated factors that 
complicate its therapeutic approach. Surgery along with ade-
quate antimicrobial therapy are essential components for the 
cure of most osteomyelitis. Further prospective and compar-
ative studies of different antimicrobial regimens and surgical 
techniques are necessary to obtain sound data that would 
allow the elaboration of therapeutic protocols aimed to ob-
tain the best possible results in the management of this diffi-
cult-to-treat infection. 
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